Clinical Trial Results:
Clinical Trials with lozenge as local anaesthesia as treatment of oral pain in burning mouth syndrome and Sjögrens syndrome
Summary
|
|
EudraCT number |
2011-006196-19 |
Trial protocol |
DK |
Global end of trial date |
15 Jan 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Sep 2019
|
First version publication date |
21 Sep 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
OC003SB
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01584947 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Clinical Research Centre, Amager and Hvidovre Hospital
|
||
Sponsor organisation address |
Kettegård allé 30, Hvidovre, Denmark,
|
||
Public contact |
Charlotte Treldal, Clinical Research Centre, Amager and Hvidovre Hospital, 0045 38626077, sugetablet@gmail.com
|
||
Scientific contact |
Charlotte Treldal, Clinical Research Centre, Amager and Hvidovre Hospital, 0045 38626077, sugetablet@gmail.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
14 Jan 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
15 Jan 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
15 Jan 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The effect of the treatment with respectively bupivacaine- and placebo lozenges on subjective symptoms in burning mouth syndrome, Sjögren's syndrome and lichen planus such as pain in the oral mucosa, oral dryness and taste disturbances
|
||
Protection of trial subjects |
NA
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Feb 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 25
|
||
Worldwide total number of subjects |
25
|
||
EEA total number of subjects |
25
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
21
|
||
From 65 to 84 years |
4
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
The participants were recruited among patients attending or referred to the Oral Medicine clinic, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, during the period from April 2012 to January 2014 | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
The inclusion criteria were a diagnosis of BMS, age of 18 to 75 years, fertile women had to use effective contraception, ability to speak and understand Danish and ability to give informed consent. The patients were diagnosed with BMS on the basis of symptoms and clinical and paraclinical investigations. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
baseline
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
The randomization allocation list was done by a statistician and was carried out using the statistical program R version 3.0.1. The containers with the lozenges were sequentially numbered and assigned period 1 or period 2 in correlation with the randomization list. The first patient then received container 1, period 1 and container 1, period 2 and so forth.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
baseline | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
baseline | ||||||||||||||||||
Investigational medicinal product name |
Bupivacaine lozenge
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Lozenge
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Lozenges containing 5 mg bupivacaine and placebo lozenges both with a size of 12-mm diameter were manufactured by direct compression, at the Pharmacy of the Capital Region, Denmark. Both the placebo and the bupivacaine lozenge were taste masked with liquorice powder as it can disguise the bitter taste of bupivacaine.
Patients were asked to take three lozenges each day in the treatment period, one after breakfast, one after lunch and one after dinner. The lozenges were administrated after meals to sustain the local anesthetic effect as long as possible. Patients were instructed to suck on the lozenge until it was completely dissolved, to avoid the use of other medical lozenges and to avoid intake of food and drinks for a minimum of 30 minutes after the lozenge was dissolved.
|
||||||||||||||||||
Investigational medicinal product name |
Placebo lozenge
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Lozenge
|
||||||||||||||||||
Routes of administration |
Oromucosal use
|
||||||||||||||||||
Dosage and administration details |
Lozenges containing 5 mg bupivacaine and placebo lozenges both with a size of 12-mm diameter were manufactured by direct compression, at the Pharmacy of the Capital Region, Denmark. Both the placebo and the bupivacaine lozenge were taste masked with liquorice powder as it can disguise the bitter taste of bupivacaine.
Patients were asked to take three lozenges each day in the treatment period, one after breakfast, one after lunch and one after dinner. The lozenges were administrated after meals to sustain the local anesthetic effect as long as possible. Patients were instructed to suck on the lozenge until it was completely dissolved, to avoid the use of other medical lozenges and to avoid intake of food and drinks for a minimum of 30 minutes after the lozenge was dissolved.
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Treatment period 1
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst | ||||||||||||||||||
Blinding implementation details |
The patients were randomized to receive bupivacaine lozenges in one treatment period and placebo lozenges in another treatment period.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Lozenge active | ||||||||||||||||||
Arm description |
The patients were randomized to receive bupivacaine lozenges | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Bupivacaine lozenge
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Lozenge
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Lozenges containing 5 mg bupivacaine and placebo lozenges both with a size of 12-mm diameter were manufactured by direct compression, at the Pharmacy of the Capital Region, Denmark. Both the placebo and the bupivacaine lozenge were taste masked with liquorice powder as it can disguise the bitter taste of bupivacaine.
Patients were asked to take three lozenges each day in the treatment period, one after breakfast, one after lunch and one after dinner. The lozenges were administrated after meals to sustain the local anesthetic effect as long as possible. Patients were instructed to suck on the lozenge until it was completely dissolved, to avoid the use of other medical lozenges and to avoid intake of food and drinks for a minimum of 30 minutes after the lozenge was dissolved.
|
||||||||||||||||||
Arm title
|
Lozenge placebo | ||||||||||||||||||
Arm description |
The patients were randomized to placebo lozenges | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Placebo lozenge
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Lozenge
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Lozenges containing 5 mg bupivacaine and placebo lozenges both with a size of 12-mm diameter were manufactured by direct compression, at the Pharmacy of the Capital Region, Denmark. Both the placebo and the bupivacaine lozenge were taste masked with liquorice powder as it can disguise the bitter taste of bupivacaine.
Patients were asked to take three lozenges each day in the treatment period, one after breakfast, one after lunch and one after dinner. The lozenges were administrated after meals to sustain the local anesthetic effect as long as possible. Patients were instructed to suck on the lozenge until it was completely dissolved, to avoid the use of other medical lozenges and to avoid intake of food and drinks for a minimum of 30 minutes after the lozenge was dissolved.
|
||||||||||||||||||
|
|||||||||||||||||||
Period 3
|
|||||||||||||||||||
Period 3 title |
Treatment period 2
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst | ||||||||||||||||||
Blinding implementation details |
The randomization allocation list was done by a statistician and was carried out using the statistical program R version 3.0.1. The containers with the lozenges were sequentially numbered and assigned period 1 or period 2 in correlation with the randomization list. The first patient then received container 1, period 1 and container 1, period 2 and so forth.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Active lozenge | ||||||||||||||||||
Arm description |
The patients were randomized to receive bupivacaine lozenges | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Bupivacaine lozenge
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Lozenge
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Lozenges containing 5 mg bupivacaine and placebo lozenges both with a size of 12-mm diameter were manufactured by direct compression, at the Pharmacy of the Capital Region, Denmark. Both the placebo and the bupivacaine lozenge were taste masked with liquorice powder as it can disguise the bitter taste of bupivacaine.
Patients were asked to take three lozenges each day in the treatment period, one after breakfast, one after lunch and one after dinner. The lozenges were administrated after meals to sustain the local anesthetic effect as long as possible. Patients were instructed to suck on the lozenge until it was completely dissolved, to avoid the use of other medical lozenges and to avoid intake of food and drinks for a minimum of 30 minutes after the lozenge was dissolved.
|
||||||||||||||||||
Arm title
|
Placebo lozenge | ||||||||||||||||||
Arm description |
The patients were randomized to receive placebo lozenges | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Bupivacaine lozenge
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Lozenge
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Lozenges containing 5 mg bupivacaine and placebo lozenges both with a size of 12-mm diameter were manufactured by direct compression, at the Pharmacy of the Capital Region, Denmark. Both the placebo and the bupivacaine lozenge were taste masked with liquorice powder as it can disguise the bitter taste of bupivacaine.
Patients were asked to take three lozenges each day in the treatment period, one after breakfast, one after lunch and one after dinner. The lozenges were administrated after meals to sustain the local anesthetic effect as long as possible. Patients were instructed to suck on the lozenge until it was completely dissolved, to avoid the use of other medical lozenges and to avoid intake of food and drinks for a minimum of 30 minutes after the lozenge was dissolved.
|
||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||
Reporting group title |
baseline
|
|||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
baseline
|
||
Reporting group description |
- | ||
Reporting group title |
Lozenge active
|
||
Reporting group description |
The patients were randomized to receive bupivacaine lozenges | ||
Reporting group title |
Lozenge placebo
|
||
Reporting group description |
The patients were randomized to placebo lozenges | ||
Reporting group title |
Active lozenge
|
||
Reporting group description |
The patients were randomized to receive bupivacaine lozenges | ||
Reporting group title |
Placebo lozenge
|
||
Reporting group description |
The patients were randomized to receive placebo lozenges |
|
|||||||||||||||||||||
End point title |
Effect | ||||||||||||||||||||
End point description |
|||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||
End point timeframe |
Each treatment period lasted for two weeks.
|
||||||||||||||||||||
|
|||||||||||||||||||||
Statistical analysis title |
Effect | ||||||||||||||||||||
Comparison groups |
Lozenge active v Lozenge placebo v Active lozenge v Placebo lozenge
|
||||||||||||||||||||
Number of subjects included in analysis |
48
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
other | ||||||||||||||||||||
P-value |
> 0.05 | ||||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||||
Parameter type |
Mean difference (final values) | ||||||||||||||||||||
Point estimate |
-5.5
|
||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
level |
95% | ||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||
lower limit |
-7.4 | ||||||||||||||||||||
upper limit |
-3.6 | ||||||||||||||||||||
Variability estimate |
Standard deviation
|
|
|||||||||||||||||
Adverse events information
|
|||||||||||||||||
Timeframe for reporting adverse events |
• Bivirkninger eller hændelser relateret til medicinen vil blive registreret fra det øjeblik, patienten modtager medicinen og de efterfølgende 24 timer.
• Opstår der bivirkninger eller hændelser vil de blive fulgt, til de er ophørt.
|
||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||
Dictionary name |
Lægemiddelstyrelsen | ||||||||||||||||
Dictionary version |
NA
|
||||||||||||||||
Reporting groups
|
|||||||||||||||||
Reporting group title |
Burning Mouth Syndrome
|
||||||||||||||||
Reporting group description |
- | ||||||||||||||||
|
|||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |